Evotec SE Share Price

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Real-time Estimate Tradegate 05:48:20 16/05/2024 pm IST 5-day change 1st Jan Change
10.4 EUR -0.81% Intraday chart for Evotec SE +7.31% -51.36%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 874M 950M 79.3B Sales 2025 * 1.04B 1.13B 94.12B Capitalization 1.86B 2.02B 169B
Net income 2024 * -29M -31.51M -2.63B Net income 2025 * 34M 36.94M 3.08B EV / Sales 2024 * 2.43 x
Net Debt 2024 * 269M 292M 24.4B Net Debt 2025 * 142M 154M 12.86B EV / Sales 2025 * 1.93 x
P/E ratio 2024 *
-63.1 x
P/E ratio 2025 *
33.2 x
Employees 5,061
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.91%
1 week+7.31%
Current month+6.26%
1 month-21.77%
3 months-24.26%
6 months-43.29%
Current year-51.36%
More quotes
1 week
9.49
Extreme 9.49
10.66
1 month
8.52
Extreme 8.52
14.22
Current year
8.52
Extreme 8.52
21.42
1 year
8.52
Extreme 8.52
24.44
3 years
8.52
Extreme 8.52
45.83
5 years
8.52
Extreme 8.52
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19/19/19
Director of Finance/CFO 51 07/23/07
Chief Operating Officer 54 01/12/01
Members of the board TitleAgeSince
Chief Executive Officer 61 19/19/19
Director/Board Member 56 19/19/19
Chairman 63 17/14/17
More insiders
Date Price Change Volume
16/24/16 10.35 -1.24% 692 656
15/24/15 10.48 +2.04% 1,405,214
14/24/14 10.27 +3.01% 1,830,577
13/24/13 9.97 +4.73% 2,080,093
10/24/10 9.52 -1.30% 1,141,574

Delayed Quote Xetra, May 16, 2024 at 05:33 pm IST

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.48 EUR
Average target price
21.99 EUR
Spread / Average Target
+109.83%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW